Safety and efficacy assessment
toxicity, toxicities, Tumor
ADVERSE EVENT, SECONDARY, TUMOR
Treatment-related toxicities were assessed according to the Common Terminology Criteria for Adverse Events, version 4.0. The MTD was determined based on toxicity during the observation period. After the observation period, the overall toxicity profiles were also considered to determine the MTD and recommended dose (RD). Tumor response and progression-free survival (PFS) were assessed using RECIST version 1.1 as secondary endpoints. Overall survival times were also assessed. The osimertinib-free interval was defined as the period between the termination of prior osimertinib therapy and enrollment in this study.